Communiqués Shield Therapeutics plc

Actions

STX

GB00BYV81293

Produits pharmaceutiques

Temps Différé London S.E. 10:02:23 02/10/2026			Varia. 5j.	Varia. 1 janv.
6,100 ^GBX	+0,83 %		+17,31 %	-38,07 %

08/09	PALMARÈS : STV pénalisé par le ralentissement de sa division Studios ; Trifast recule	AN
01/09	Transcript : Shield Therapeutics plc - Special Call

Communiqués

03/12	Shield Therapeutics : Amends Senior Secured Debt Financing with improved terms	PU
24/10/25	Shield Therapeutics : Q3 2025 Trading Update	PU
01/10/25	Shield Therapeutics : ACCRUFeR® Phase 3 pediatric trial presentation at the American Association of Pediatrics (AAP) Conference	PU
21/08/25	Shield Therapeutics : Interim results for the six months ended 30 June 2025	PU
22/05/25	Shield Therapeutics : Results of 2025 AGM	PU
25/04/25	Shield Therapeutics : Annual Report and Accounts for the year ended 2024	PU
25/04/25	Shield Therapeutics : Letter to shareholders	PU
24/04/25	Shield Therapeutics : 2024 Full Year Results & Q1 2025 Presentation	PU
28/02/25	Shield Therapeutics : Corporate Presentation	PU
24/02/25	Shield Therapeutics : Anders Lundstrom CEO - 2024 Year in Review & Strategic Outlook for 2025	PU
06/12/24	Shield Therapeutics : AOP Relationship Agreement	PU
06/12/24	Shield Therapeutics : AOP Subscription Agreement	PU
06/12/24	Shield Therapeutics : Director's Irrevocable Undertaking - Hans Peter Hasler	PU
06/12/24	Shield Therapeutics : Director's Irrevocable Undertaking - Anders Lundstrom	PU
06/12/24	Shield Therapeutics : Director's Irrevocable Undertaking - Dr Christian Schweiger	PU
06/12/24	Shield Therapeutics : Director's Irrevocable Undertaking Fabiana Lacerca Allen	PU
06/12/24	Shield Therapeutics : Peel Hunt Consent Letter	PU
06/12/24	Shield Therapeutics : AOP Irrevocable Undertaking	PU
06/12/24	Shield Therapeutics : Shareholder Circular	PU
06/12/24	Shield Therapeutics : Subscription by AOP Health to raise US$10 million, RetailBook Offer and Notice of General Meeting	PU
06/12/24	Shield Therapeutics : Articles of Association of AOP Health International Management AG	PU
06/12/24	Shield Therapeutics : Directors's Irrevocable Undertakings P Llewellyn Davies	PU
21/11/24	Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven	EQ
21/11/24	Shield Therapeutics : Q4 Business Update	PU
11/11/24	Hardman & Co Video Event: Shield Therapeutics (STX) Investor Forum	EQ